Communiqués Sionna Therapeutics, Inc.

Actions

SION

US8294011080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
7,180 ^USD	+1,99%		-5,77%	-82,55%

15/09	Sionna Therapeutics, Inc. : Wedbush maintient son opinion neutre	ZM
15/09	Transcript : Sionna Therapeutics, Inc. - Special Call

Communiqués

14/09	Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial	GL
19/08	Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm	BU
10/08	Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update	GL
06/08	Sionna Therapeutics Reports Second Quarter 2026 Financial Results	GL
27/05	Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences	GL
13/05	Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	GL
13/05	Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	AQ
12/05	Sionna Therapeutics Reports First Quarter 2026 Financial Results	GL
27/04	Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis	GL
07/04	Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium	GL
02/03	Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	GL
23/02	Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences	GL
04/02	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026	GL
04/02	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026	AQ
05/01	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
24/11	Sionna Therapeutics to Participate in Upcoming December Investor Conferences	GL
05/11	Sionna Therapeutics Reports Third Quarter 2025 Financial Results	AQ
05/11	Sionna Therapeutics Reports Third Quarter 2025 Financial Results	GL
04/11	Sionna Therapeutics to Participate in Upcoming November Investor Conferences	GL
24/10/25	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference	GL
21/10/25	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis	GL
01/10/25	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference	GL
08/09/25	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer	GL
08/09/25	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer	AQ
27/08/25	Sionna Therapeutics to Participate in Upcoming September Investor Conferences	AQ